ReviewJournal of global infectious diseases
Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat.
Review in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 105 citations in OpenAlex.
- Comparative Evaluation of Real-Time PCR, Immunochromatographic Assay, and Modified Carbapenem Inactivation Method for Carbapenemase Detection in Enterobacterales Isolates.International journal of molecular sciences · 2026Article
- An Overview of Virulence, Resistance, and Clinical Significance of Klebsiella Infections.Cureus · 2026Review
- Genomic insights into antimicrobial resistance in ocular pathogens from India.Communications biology · 2026Article
- The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producingJAC-antimicrobial resistance · 2026Review
- Rapid Detection of Carbapenemase-Producing Enterobacterales Using a Luminescent Whole-Cell Biosensor.ACS infectious diseases · 2026Article
- Mechanisms, Significance, Detection and Emerging Therapies for Carbapenem-Resistant Enterobacterales: A Scoping Review.Journal of tropical medicine · 2026Review
- One Health genomic surveillance ofFrontiers in microbiology · 2026Article
- Evaluation of the rapid lateral flow assay (LFA) for detection of five major carbapenemase enzyme families in genotypically characterised bacterial isolates.The Indian journal of medical research · 2025Article
- In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing enterobacterales.The Journal of antibiotics · 2025Article
- Assessment of Phenotypic Tools for Detection of OXA-48, KPC, and NDM inDiagnostics (Basel, Switzerland) · 2025Article
- Emergence of population heterogeneity in Klebsiella pneumoniae with a blaJournal of biomedical science · 2025Article
- Article
- Epidemiological and genetic characteristics of clinical carbapenemase-producing Enterobacterales isolates from Batna hospitals in Algeria.BMC infectious diseases · 2024Article
- Performance of Ertapenem-Supplemented MacConkey Agar (MacErt) for Detecting Carbapenemase-Producing Enterobacterales.Cureus · 2024Article
- Evaluation of the Xpert Carba-R assay for quantifying carbapenemase-producing bacterial load in stool samples.PloS one · 2024Article
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- AcquiredPathogens (Basel, Switzerland) · 2023Article
- CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases.Microbiology spectrum · 2023Article
- Characterisation of OXA-48-like carbapenemases in3 Biotech · 2023Article
- Direct Detection of KPC Peak from Positive Blood Cultures Using MALDI-TOF MS: Are We There Yet?Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenemase producing Gram-negative pathogen is of great concern for physician. The challenging aspects are treatment option and infection control. Monitoring of respective carbapenemase resistance mechanism is necessary to prevent the outbreaks. Currently, the rapid emergence of oxacillinase (OXA-48) like is alarming. Increasing frequency of OXA-48 is seen than the classical carbapenemase (KPC, NDM, IMP, and VIM) across the world. The bla OXA-48 gene is commonly identified in Escherichia coli and Klebsiella pneumoniae. The transferrable plasmid of OXA-48 is associated with rapid spread and inter-species dissemination. In general, OXA-48-like enzymes weakly hydrolyzes both carbapenem and broad spectrum cephalosporins. Except OXA-163, which effectively hydrolyze cephalosporin. This poor hydrolytic profile obscures the detection of OXA-48-like. It may go undetected in routine diagnosis and complicates the treatment option. Co-production of OXA-48-like with CTX-M-15 and other carbapenemase (NDM, VIM) leads to the emergence of multidrug resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.